AI And Data Expansion Will Define Future Potential While Current Risks Keep Expectations Tame

Veeva Systems' updated analyst price target has been reduced from about $232.80 to $165.00. Analysts cite slightly lower modeled revenue growth, a lower assumed future P/E multiple, and ongoing debates around AI disruption and competitive pressure in core CRM offerings, despite steady Q1 execution and continued AI product development.

Analyst Commentary

Recent Street research on Veeva Systems shows a wide range of views, but with a clear tilt toward more cautious pricing of the stock. Many firms have reset their valuation frameworks, often pushing out time horizons and trimming price targets, even where ratings remain positive. The mix of solid Q1 execution, questions around core CRM durability, and the evolving AI story is driving a more balanced, and in some cases clearly bearish, stance.

Several price targets on Veeva have been revised lower, even as Q1 results were described as solid or steady in many of the research notes. While there are still Overweight, Buy, and Outperform ratings in place, the compression in targets suggests analysts are paying closer attention to growth quality, the contribution from services, and possible pressure on core subscription products.

JPMorgan moved its Veeva target to US$272 from US$296 as part of a broader reset in health technology, extending its horizon to year end 2027. That adjustment reflects a more measured view on how long it may take for demand drivers to play through the model. At the same time, Goldman Sachs cut its target to US$165 from US$190 and kept a Sell rating, pointing to a modest Q1 beat that leaned on Professional Services and ongoing debates about maturing core offerings and AI related positioning.

Other research flags similar themes. Some firms highlight a Q1 beat and guidance that still leaves room for upside if trends continue, but they also emphasize concerns around CRM customer retention, potential Top 20 pharma CRM share shifts to competitors, and the mix of growth coming from services rather than subscriptions. Several analysts point to AI as a double edged factor, with management investing in products such as Falcon and acquisitions like Ostro, while investors continue to question how and when AI efforts could translate into durable, high margin growth.

Across the board, the research set underscores that Veeva Systems is executing on near term objectives but remains under scrutiny around longer term competitive positioning in CRM and the quality of its revenue mix. For investors, the key questions flagged by the Street revolve around how much to pay for the current growth profile, what happens to CRM share among large pharma clients, and how AI disruption risk is priced into the stock.

Bearish Takeaways

• Bearish analysts cut price targets significantly, in some cases down to the mid US$100s, citing a modest Q1 beat that was driven more by Professional Services than by core subscription strength, which raises questions about the durability and quality of growth.
• Several cautious notes highlight concerns that Veeva's core CRM offerings may be maturing, with ongoing debates about competitive pressure and the risk of further Top 20 pharma CRM share losses, which could weigh on long term growth expectations.
• AI disruption risk is a recurring theme, with bearish analysts arguing that current AI products and catalysts, including Falcon, may not yet be enough to offset concerns around the core business and could limit how much investors are willing to pay on a P/E basis.
• Some research characterizes the recent quarter as solid but imperfect, with upside skewed toward services and M&A related contributions, which these analysts see as less attractive than subscription driven growth and a potential source of ongoing valuation pressure if the mix persists.

What’s in the News for Veeva Systems

• Veeva Systems announced the acquisition of Copli and launched Veeva Falcon MLR, an AI driven platform aimed at automating medical, legal, and regulatory content review. The company also expanded Veeva Quality Cloud with the new Veeva EHS application for environmental, health, and safety management. (Source: company announcements summarized in recent news)
• Veeva reported Q1 fiscal 2027 results with adjusted EPS of US$2.24 and revenue of US$882.9 million. The company also provided guidance for Q2 and full year fiscal 2027 that is above analyst expectations in the cited coverage, and has a Zacks Rank of #3 (Hold). (Source: Q1 fiscal 2027 earnings coverage)
• Management issued updated guidance for fiscal 2027, with total revenues expected between US$3.635 billion and US$3.645 billion. Veeva also guided Q2 fiscal 2027 total revenues to a range of US$902 million to US$905 million. (Source: company guidance update)
• Veeva Systems announced Veeva Falcon, an agentic platform for major drug development processes, along with Vault AI Agents and plans to extend Vault AI across all Vault applications. The company also detailed early adopter timing for Veeva Falcon and Veeva EHS. (Source: product related announcements)
• Veeva Systems stock was added to several S&P indices, including the S&P 500, S&P 500 Growth, S&P 500 Value, S&P 500 Equal Weighted, S&P 500 Health Care sector and industry group indices, and the S&P Composite 1500 and S&P Global 1200. At the same time, it was removed from multiple Russell growth benchmarks. (Source: index constituent changes)

Valuation Changes for Veeva Systems

• Fair Value: reset from $232.80 to $165.00, a reduction of about 29%, reflecting more cautious assumptions built into the model.
• Discount Rate: adjusted slightly, from 8.24% to 8.02%, indicating only a small change in the risk or return hurdle applied to Veeva Systems.
• Revenue Growth: trimmed from 11.86% to 10.80%, signaling a more conservative view on the pace of future top line expansion.
• Net Profit Margin: nudged higher from 27.87% to 28.86%, implying a modestly stronger long run profitability assumption despite softer growth inputs.
• Future P/E: reduced meaningfully from 41.64x to 25.22x, pointing to a lower valuation multiple being applied to Veeva Systems relative to prior expectations.